ION-269 / Ionis - LARVOL DELTA

Ionis scraps early candidate for Alzheimer’s in people with Down syndrome (FierceBiotech) - "'This decision was made based on multiple factors, including slow enrollment, and is not related to concerns with the study drug.'...Ionis has now shut down the trial with just one patient enrolled, according to the federal clinical trial database."

Discontinued • Trial termination • Alzheimer's Disease • CNS Disorders

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Ionis Pharmaceuticals, Inc. | Trial completion date: Mar 2027 ➔ Dec 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Feb 2027 ➔ Dec 2025; Sponsor decision to terminate study early. Decision not based on safety concerns.

Trial completion date • Trial primary completion date • Trial termination • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | N=30 ➔ 1

Enrollment change • Enrollment closed • Alzheimer's Disease • CNS Disorders • Developmental Disorders • Genetic Disorders